Sumitomo Dainippon Pharma Annual Report 2017
82/102

Millions of yenThousands ofU.S. dollars201620172017¥ 38,785———Millions of yenCostUnrealizedlossesFair value¥ 0———Unrealized gains¥ 26,133———¥ 12,652———2017 Available-for-sale securities: Equity securities Government / local government bonds Corporate bonds Other securities¥ 51,644———Millions of yenCostUnrealizedlossesFair value¥ 184———Unrealized gains¥ 36,017———¥ 15,811———2016 Available-for-sale securities: Equity securities Government / local government bonds Corporate bonds Other securities $ 346,295———Thousands of U.S. dollarsCostUnrealizedlossesFair value$ 0———Unrealized gains$ 233,331———$ 112,964———2017 Available-for-sale securities: Equity securities Government / local government bonds Corporate bonds Other securities ——$ 35,714269,599$ 305,313$ 346,295—$ 346,295——¥ 11,10069,939¥ 81,039¥ 51,644—¥ 51,644——¥ 4,00030,195¥ 34,195¥ 38,785—¥ 38,785Current: Government / local government bonds Corporate bonds Negotiable certicates of deposits MMF Total Noncurrent: Equity securities Trust fund investments and other Total Marketable securities and investment securities as of March 31, 2017 and 2016 consisted of the following:The carrying amount and aggregate fair value of marketable securities and investment securities as at March 31, 2017 and 2016 were as follows:6. MARKETABLE SECURITIES AND INVESTMENT SECURITIESNotes to Consolidated Financial StatementsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016Financial SectionSumitomo Dainippon Pharma Co., Ltd. Annual Report 201781

元のページ  ../index.html#82

このブックを見る